These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 7292420)

  • 41. [Drug dosage and contra-indications in neonate, infant and child (author's transl)].
    Pellegrin P; Lesne M
    J Pharm Belg; 1980; 35(4):289-300. PubMed ID: 7441479
    [No Abstract]   [Full Text] [Related]  

  • 42. Interpretation and considerations on the safety evaluation of human drug metabolites.
    Atrakchi AH
    Chem Res Toxicol; 2009 Jul; 22(7):1217-20. PubMed ID: 19563206
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Organization and results of drug vigilance in France].
    Bégaud B; Chaslerie A; Haramburu F
    Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Receptor occupation theory and its parameter estimates (author's transl)].
    Xu DZ
    Sheng Li Ke Xue Jin Zhan; 1981 Oct; 12(4):318-24. PubMed ID: 7344074
    [No Abstract]   [Full Text] [Related]  

  • 45. Building an ontology of adverse drug reactions for automated signal generation in pharmacovigilance.
    Henegar C; Bousquet C; Lillo-Le Louët A; Degoulet P; Jaulent MC
    Comput Biol Med; 2006; 36(7-8):748-67. PubMed ID: 16185681
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Equilibrium sampling through membrane based on a single hollow fibre for determination of drug-protein binding and free drug concentration in plasma.
    Trtić-Petrović T; Liu JF; Jönsson JA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Nov; 826(1-2):169-76. PubMed ID: 16181816
    [TBL] [Abstract][Full Text] [Related]  

  • 47. European commission consultation on pharmacovigilance.
    Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
    [No Abstract]   [Full Text] [Related]  

  • 48. AIHP Kremers Award Address 2006. Pharmacovigilance and the missing denominator: the changing context of pharmaceutical risk mitigation.
    Daemmrich A
    Pharm Hist; 2007; 49(2):61-75. PubMed ID: 18368740
    [No Abstract]   [Full Text] [Related]  

  • 49. Drug therapy: safety, effectiveness, and economics.
    Brandys J
    Przegl Lek; 2001; 58(4):226-8. PubMed ID: 11450340
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Sampling design of linear one compartment open model for drug administered via non-blood-vessel way (author's transl)].
    Zhang WG
    Yao Xue Xue Bao; 1981 Oct; 16(10):732-40. PubMed ID: 7336933
    [No Abstract]   [Full Text] [Related]  

  • 51. Prediction of milk/plasma concentration ratio of drugs.
    Ilett KF; Hackett LP
    Ann Pharmacother; 2004 Jan; 38(1):175-6; author's reply 176. PubMed ID: 14742820
    [No Abstract]   [Full Text] [Related]  

  • 52. [Species differences in drug metabolism - overview from animals to man (author's transl)].
    Kato R
    Jikken Dobutsu; 1981 Oct; 30(4):507-17. PubMed ID: 7318948
    [No Abstract]   [Full Text] [Related]  

  • 53. Prediction of milk/plasma concentration ratio of drugs.
    Doogue MP; Gardiner SJ; Begg EJ
    Ann Pharmacother; 2004 Jan; 38(1):174-6; author's reply 176. PubMed ID: 14742819
    [No Abstract]   [Full Text] [Related]  

  • 54. [Pharmacovigilance seen by a selected group of general practitioners and of residents in the Midi-Pyrénées region].
    Pouget-Zago P; Lapeyre-Mestre M; Bagheri H; Montastruc JL
    Therapie; 1995; 50(5):459-62. PubMed ID: 8571286
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Values and limitations in the measurement of plasma concentrations of drugs].
    Singlas E; Bonnat C; Simon P
    Rev Prat; 1982 Sep; 32(41-42):2665-6 passim. PubMed ID: 7146803
    [No Abstract]   [Full Text] [Related]  

  • 56. [Why measure drug metabolites?].
    Hendset M; Hermann M
    Tidsskr Nor Laegeforen; 2007 Jun; 127(13):1786-8. PubMed ID: 17599129
    [No Abstract]   [Full Text] [Related]  

  • 57. [Apropos of a prospective systematic survey of pharmacovigilance in chemist's shops].
    Leclerc C; Debas A; Bagheri H; Montastruc JL
    Therapie; 1996; 51(5):563-4. PubMed ID: 9138397
    [No Abstract]   [Full Text] [Related]  

  • 58. [Bioavailability: concept and problems (author's transl)].
    Balant L
    J Pharm Belg; 1980; 35(5):369-76. PubMed ID: 7452443
    [No Abstract]   [Full Text] [Related]  

  • 59. [PSUR - Instrument for pharmacovigilance and patient safety. What pharmacists should know about periodic safety update reports].
    Strehl E
    Med Monatsschr Pharm; 2009 Sep; 32(9):347-9. PubMed ID: 19795697
    [No Abstract]   [Full Text] [Related]  

  • 60. [Retrospective study of adverse drug reactions in the elderly: experience of regional center for pharmacovigilance].
    Bruneau S; Bruhat C; Lagarce L; Lainé-Cessac P
    Therapie; 2001; 56(6):785-91. PubMed ID: 11878111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.